DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026 Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif.,

LONDON, 29 Jan. 2026 (GLOBE NEWSWIRE) — This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by Notified and is designated by the FCA as an approved

Riverton, Wyoming, Jan. 28, 2026 (GLOBE NEWSWIRE) — Central Wyoming College (CWC) recognizes the academic achievements of its students by announcing those named to the President’s List and Dean’s List

PHILADELPHIA, Jan. 28, 2026 (GLOBE NEWSWIRE) — Callan Family Office, a registered investment advisor serving ultra-high-net-worth families, family offices, foundations, and endowments across the United States, today announced that it

VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) — Atico Mining Corporation (TSX.V: ATY | OTCID: ATCMF) (“Atico” or the “Company”) is pleased to announce positive results from 21 drill

Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026Idorsia Ltd

Not for distribution to U.S. newswire services or for dissemination in the United States Vancouver, BC, Jan. 27, 2026 (GLOBE NEWSWIRE) — Aben Gold Corp. (TSX-V: ABM) (OTCID: ABNAF) (Frankfurt: ML1) (“Aben” or

Charleston, SC, Jan. 27, 2026 (GLOBE NEWSWIRE) — In a world before cellphones and the internet, young Stewart faces a daunting diagnosis of Acute Lymphocytic Leukemia, labeled by doctors at

– ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype – WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a

DURHAM, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) — Since its founding in 2005, Open Invention Network (OIN) has been the only organization focused on mitigating patent risk in open source

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd)

In a release issued under the same headline earlier today by Waldencast plc (NASDAQ: WALD), please note that the quote by Michael Pennington in paragraph 3 was incorrect. The corrected

LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) — Small and medium-sized enterprises (SMEs) across the UK’s engineering and manufacturing sector, are being given a chance to share their experiences, priorities, and

New York, USA, Jan. 26, 2026 (GLOBE NEWSWIRE) — WealthW-Group today announced the implementation of a governance-focused operational strategy for its activities within the digital asset sector. The firm’s approach

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date